AEON Biopharma (NASDAQ:AEON) Upgraded by Zacks Research to Hold Rating

Posted by Linda Flegge on May 29th, 2026

AEON Biopharma (NASDAQ:AEON – Get Free Report) was upgraded by research analysts at Zacks Research to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

AEON Biopharma Trading Down 4.5%

NASDAQ AEON opened at $0.72 on Wednesday. The stock’s 50-day moving average price is $0.94 and its two-hundred day moving average price is $1.00. The company has a market cap of $18.12 million, a PE ratio of 3.98 and a beta of 0.66. AEON Biopharma has a 1 year low of $0.53 and a 1 year high of $1.45.

Hedge Funds Weigh In On AEON Biopharma

An institutional investor recently raised its position in AEON Biopharma stock. XTX Topco Ltd raised its holdings in shares of AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) by 251.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,852 shares of the company’s stock after acquiring an additional 40,690 shares during the quarter. XTX Topco Ltd owned approximately 0.48% of AEON Biopharma worth $63,000 at the end of the most recent quarter. Institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

(Get Free Report)

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.